Method for producing radioactive metal complex

By using a water-soluble organic compound with a sulfo or carboxyl group as a buffer in the radioactive metal complex formation reaction and microwave irradiation is performed when the reaction liquid is cooled, the problem that the microwave irradiation conditions in the prior art has not been studied in detail. The reaction efficiency and yield are improved, and efficient preparation of radioactive metal complexes is achieved.

CN119095830APending Publication Date: 2024-12-06NIHON MEDI PHYSICS CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380036172.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-27
Filing Date
2023-04-20
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The conditions for microwave irradiation in the radioactive metal complex formation reaction in the prior art have not been studied in detail, resulting in the failure to maximize the reaction efficiency, and there is room for improvement in the reaction efficiency.

Method used

In the reaction solution containing water and a buffer, a water-soluble organic compound with a sulfo or carboxyl group is used as a buffer, and microwave irradiation is performed while the reaction solution is cooled to improve the reaction efficiency of the radioactive metal nuclide and the ligand compound. .

Benefits of technology

This method significantly improves the formation efficiency and yield of radioactive metal complexes, shortens the reaction time, reduces the occurrence of side reactions, and improves the stability and simplicity of operation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095830A_ABST
    Figure CN119095830A_ABST
Patent Text Reader

Abstract

A method for producing a radioactive metal complex, the method comprising a complex formation step in which a radioactive metal nuclide and a ligand compound represented by formula (1) are reacted in a reaction solution containing water and a buffer agent containing one or more water-soluble organic compounds having a sulfo group or a carboxyl group to form a radioactive metal complex, in the complex formation step, the reaction liquid is irradiated with microwaves while cooling the reaction liquid. It is preferable that the radioactive metal nuclide is 68 Ga, 89 Zr, 90 Y, 111 In, 177 Lu, or 225 Ac. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing a radioactive metal complex. Background Art

[0002] For the purpose of using in reagents and diagnostic agents for detecting target molecules or pharmaceuticals for treating diseases, research is being conducted to efficiently synthesize radioactive metal complexes obtained by coordinating ligand compounds to radioactive metal nuclides. As one of such studies, microwave irradiation can be cited when performing a reaction (hereinafter, also referred to as a "radioactive metal complex formation reaction") in which a ligand compound is coordinated to a radioactive metal nuclide.

[0003] Patent document 1 records 225 The method for producing a radioactive metal complex labeled with Ac. 225 When heating is required during the formation reaction of the radioactive metal complex of Ac, heating by microwave irradiation is preferred.

[0004] Non-patent document 1 describes a method comprising 68 The document discloses a method for producing a radioactive metal complex of Ga and DOTATOC as a ligand compound. The document states that the target metal complex can be obtained in a shorter time than when heating with a block heater by irradiating microwaves to 90°C during the radioactive metal complex formation reaction. 68 Ga complex.

[0005] Non-patent document 2 contains 89 A method for producing a radioactive metal complex of Zr and TRITA as a ligand compound. The document states that by irradiating the radioactive metal complex with microwaves and heating it to 180°C during the radioactive metal complex formation reaction, the target metal can be obtained in a shorter time and with a higher yield than in the case of using a conventional heating method. 89 Zr complex.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: U.S. Patent Application Publication No. 2015 / 0157742

[0009] Non-patent literature

[0010] Non-patent document 1: I. Velikyan et al., Bioconjugate Chem. 2004, 15, 554-560

[0011] Non-patent document 2: D.N.Pandya et al., Inorg.Chem.2020,59,17473-17487 Summary of the invention

[0012] Problems to be solved by the invention

[0013] Patent Document 1, Non-Patent Document 1 and Non-Patent Document 2 do not study the detailed conditions of microwave irradiation in the radioactive metal complex formation reaction. Therefore, the reaction acceleration effect brought about by microwave irradiation cannot be maximized, and there is room for improvement in the reaction efficiency of the radioactive metal complex formation reaction.

[0014] Therefore, an object of the present invention is to more efficiently carry out a radioactive metal complex forming reaction.

[0015] The present invention provides a method for producing a radioactive metal complex, comprising a complex forming step of reacting a radioactive metal nuclide with a ligand compound represented by the following formula (1) in a reaction solution containing water and a buffer to form a radioactive metal complex.

[0016] The buffer comprises one or more water-soluble organic compounds having a sulfonic group or a carboxyl group,

[0017] In the complex forming step, the reaction solution is irradiated with microwaves while the reaction solution is cooled.

[0018] [Chemical formula 1]

[0019]

[0020] (In formula (1), R 11 , R 12 and R 13 Each independently consists of -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, or -(CH2) p The group composed of CONH2, R 14 or R 15 One of them is composed of hydrogen atoms, -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, -(CH2) p CONH2, or, -(CHCOOH)(CH2) p COOH, and the other is -(CH2)pCOOH, -(CH2) p C5H4N, -(CH2)p PO3H2, or -(CH2) p CONH2, or a reactive atomic group for connecting to a targeting agent or a group connected to a targeting agent, and p is independently an integer of 0 to 3.

[0021] According to the present invention, there is provided a method for producing a radioactive metal complex, which enables a radioactive metal complex-forming reaction to proceed more efficiently. DETAILED DESCRIPTION

[0022] The method for producing a radioactive metal complex of the present invention is described below based on preferred embodiments thereof. The method of the present invention comprises a complex forming step of reacting a radioactive metal nuclide with a ligand compound represented by formula (1) described below in a reaction solution to form a radioactive metal complex.

[0023] The radioactive metal complex is a compound in which a radioactive metal atom is bonded to a ligand compound through a combination of coordination bonds, covalent bonds, ionic bonds, etc., and also includes a compound further bonded with a reactive atomic group or a targeting agent described later.

[0024] In the present specification, forming a complex between a radioactive metal ion and a ligand compound is synonymous with labeling the ligand compound with the radioactive metal ion, and the complex formation efficiency is synonymous with the labeling rate.

[0025] From the viewpoint of improving the labeling rate, the radioactive metal nuclide used in the complex formation step is preferably used in the form of a compound that can be ionized in water, and more preferably in the form of a metal ion (hereinafter, these forms are also collectively referred to as "radioactive metal sources"). As the radioactive metal source, for example, a liquid containing radioactive metal ions obtained by dissolving or dispersing radioactive metal ions in a solvent mainly composed of water can be used.

[0026] The radioactive metal nuclide contained in the radioactive complex of the present invention is an α-ray emitting radionuclide, a β-ray emitting radionuclide, a positron emitting radionuclide or a γ-ray emitting radionuclide. When the radioactive complex of the present invention is used for cancer treatment, it is preferred to use an α-ray emitting radionuclide or a β-ray emitting radionuclide. In addition, when the radioactive complex of the present invention is used for diagnosis or detection of cancer, it is preferred to use a positron emitting radionuclide or a γ-ray emitting radionuclide. Examples of the α-ray emitting radionuclide include 212 Bi, 213 Bi, 225 Ac, 227 Th. In addition, examples of radionuclides that emit β rays include 64 Cu,90 Y or 177 Lu. In addition, examples of radionuclides that emit positrons include 64 Cu, 68 Ga, 86 Y. 89 Zr. In addition, as radioactive nuclides that emit gamma rays, there are 99m Tc or 111 In. The radioactive metal nuclide contained in the radioactive composite of the present invention is more preferably 225 Ac, 90 Y. 177 Lu or 89 Zr.

[0027] The concentration of the radioactive metal nuclide in the reaction solution is preferably from 1 nmol / L to 10000 nmol / L, more preferably from 1 nmol / L to 5000 nmol / L, further preferably from 1 nmol / L to 1000 nmol / L, and more preferably from 1 nmol / L to 500 nmol / L, at the start of the reaction between the radioactive metal nuclide and the ligand compound (hereinafter also referred to as "the start of the complex formation step" or "the start of the reaction").

[0028] The radioactive metal nuclide can be dissolved in a suitable solvent after production and stored in a solution state, and when necessary, a required amount can be taken out from the solution and used in the present invention. Hereinafter, the solution used to store the radioactive metal nuclide is also referred to as a "bulk solution".

[0029] If the radioactive decay of the radionuclide proceeds, the amount of bulk solution required for the complex formation reaction increases in terms of the desired radioactivity. The non-radioactive metal used when the radioactive metal nuclide is manufactured is mixed into the bulk solution. Therefore, if the amount of bulk solution used increases, the amount of non-radioactive metal mixed in the complex formation reaction also increases, which becomes the main reason for reducing the yield of the complex formation reaction, so the radionuclide is preferably used quickly after manufacturing.

[0030] The ligand compound used in the complex forming step has a structure represented by the following formula (1).

[0031] [Chemical formula 2]

[0032]

[0033] In formula (1), R 11 , R 12 and R 13 Each independently consists of -(CH2) p COOH, -(CH2)p C5H4N, -(CH2) p PO3H2, or -(CH2) p The group composed of CONH2.

[0034] The above p is each independently an integer of 0 to 3.

[0035] In formula (1), R 14 or R 15 One of them is composed of hydrogen atoms, -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, -(CH2) p CONH2, or, -(CHCOOH)(CH2) p The group composed of COOH.

[0036] In formula (1), R 14 or R 15 The other is -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, or -(CH2) p The group formed by CONH2 is either a reactive atomic group used to connect with a targeting agent or a group that has been connected with a targeting agent.

[0037] The above p is each independently an integer of 0 to 3.

[0038] Details of the targeting agent and the reactive atomic group for linking to the targeting agent or the group already linked to the targeting agent are described later.

[0039] More specifically, the ligand compound used in the complex forming step further preferably contains one compound shown below or a structure derived from the compound. The ligand compound used in the complex forming step is preferably water-soluble.

[0040] DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)

[0041] DOTMA((1R,4R,7R,10R)-α,α',α",α"'-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)

[0042] DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane)

[0043] DOTA-GA (α-(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)

[0044] DOTP (((1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetra(methylene))tetraphosphonic acid)

[0045] DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid))

[0046] DOTA-4AMP(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamidomethylidenephosphonic acid)

[0047] DO2P (tetraazacyclododecane dimethanephosphonic acid)

[0048] From the viewpoint of improving the yield of the target radioactive metal complex, at the beginning of the complex formation step, the concentration of the ligand compound in the reaction solution is preferably from 1 μmol / L to 1000 μmol / L, more preferably from 1 μmol / L to 900 μmol / L, further preferably from 1 μmol / L to 600 μmol / L, and more preferably from 1 μmol / L to 500 μmol / L.

[0049] The reaction solution in the complex formation step is an aqueous reaction solution containing water and a buffer.

[0050] As the water, water generally used in the present technical field can be adopted, for example, distilled water or ion-exchanged water can be used.

[0051] The buffer contains a water-soluble organic compound having a predetermined structure. The water-soluble organic compound is an organic compound that dissolves in water and is a compound different from the above-mentioned ligand compound. Therefore, the water-soluble organic compound in this specification is not included in the ligand compound.

[0052] In the following description, a water-soluble organic compound having a predetermined structure and not included in the ligand compound and the organic solvent is also referred to as a "second organic compound".

[0053] One of the characteristics of the second organic compound contained in the reaction solution is that it has a specific functional group in its structure. Specifically, as one embodiment of the second organic compound, it has a sulfonic group in its structure. The sulfonic group is composed of "-SO3H" or "-SO3 - " is a monovalent functional group represented by. From the viewpoint of easy availability, reduced production cost, and increased yield of the radioactive metal complex, the second organic compound in this embodiment preferably has one or two sulfonic groups, that is, preferably a monosulfonic acid or a disulfonic acid.

[0054] When the second organic compound has a sulfonic group in its structure, the total number of carbon atoms of the second organic compound is preferably 4 to 10, more preferably 6 to 8.

[0055] In addition, when a sulfonic group is present in the structure, the second organic compound preferably has a heteroatom in the structure, preferably has at least a nitrogen atom in the structure, further preferably has a cyclohexane ring or a heterocyclic ring in the structure, more preferably contains a saturated heterocyclic ring having 2 nitrogen atoms, or a nitrogen atom and an oxygen atom in the structure, and further preferably contains a morpholine ring or a piperazine ring in the structure.

[0056] When the sulfonic acid group is present in the structure, it is also preferred that an alkanesulfonic acid group is present in the structure, and it is also preferred that the alkanesulfonic acid group is bonded to a heteroatom, and it is more preferred that an aminoalkanesulfonic acid group is present in the structure.

[0057] In any of the above cases, the second organic compound having a sulfo group in its structure is preferably a zwitterionic compound, and more preferably an aminoalkanesulfonic acid derivative.

[0058] As the second organic compound having one sulfonic group in its structure, for example, there can be mentioned chain amine monosulfonic acids such as N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); monosulfonic acids having a morpholine ring such as 2-morpholineethanesulfonic acid (MES) and 3-morpholinepropanesulfonic acid (MOPS); monosulfonic acids having a piperazine ring such as 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid (HEPES); and / or salts thereof, etc.

[0059] Examples of the second organic compound having two sulfonic groups in its structure include disulfonic acids having a piperazine ring in its structure, such as 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid (HEPES) and piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), and / or salts thereof.

[0060] Examples of the counter ion of the second organic compound having a sulfonic group in its structure include alkali metal ions such as sodium and potassium, cations such as primary to quaternary ammonium such as ammonium and tetramethylammonium salts, and anions such as halogens such as chlorine.

[0061] Another embodiment of the second organic compound contained in the reaction solution has a carboxyl group in its structure. The carboxyl group is represented by "-COOH" or "-COO - " is a monovalent functional group represented by. From the viewpoint of easy availability, reduced production cost, and increased yield of the radioactive metal complex, the second organic compound in this embodiment preferably has one or two carboxyl groups, that is, preferably a monocarboxylic acid or a dicarboxylic acid.

[0062] When the second organic compound has a carboxyl group in its structure, the total number of carbon atoms of the second organic compound is preferably 2 to 10, more preferably 2 to 8.

[0063] When the second organic compound has a carboxyl group in its structure, it is preferably a saturated or unsaturated aliphatic carboxylic acid or an aromatic carboxylic acid, and more preferably a saturated aliphatic carboxylic acid.

[0064] Examples of the second organic compound having one carboxyl group in its structure include linear aliphatic monocarboxylic acids such as acetic acid and lactic acid; aromatic monocarboxylic acids such as benzoic acid and salicylic acid; and / or salts thereof.

[0065] Examples of the second organic compound having two carboxyl groups in the structure include linear aliphatic dicarboxylic acids such as malonic acid and tartaric acid, aromatic dicarboxylic acids such as phthalic acid, and / or salts thereof.

[0066] Examples of the counter ion of the second organic compound having a carboxyl group in its structure include alkali metal ions such as sodium and potassium, and primary to quaternary ammonium cations such as ammonium and tetramethylammonium salts.

[0067] Among them, as the second organic compound having a sulfonic group or a carboxyl group in the structure, it is further preferred to use one or more selected from acetic acid, phthalic acid, malonic acid, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid or 2-morpholineethanesulfonic acid and salts thereof, and it is more preferred to use one or more selected from acetic acid or 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid and salts thereof.

[0068] The reaction liquid containing an appropriate second organic compound can be used in the complex formation step in a state of being prepared in advance as an aqueous solution containing these organic compounds. They can be a buffer solution that exerts a pH buffering effect in the complex formation step, or they can be a liquid that does not exert a pH buffering effect.

[0069] From the viewpoint of further improving the labeling efficiency, the concentration of the second organic compound in the reaction solution is preferably 0.01 mol / L to 2.0 mol / L, and more preferably 0.1 mol / L to 1.0 mol / L at the start of the complex formation step.

[0070] The reaction solution may include a stabilizer in addition to water and a buffer. The stabilizer included in the reaction solution is a substance or a salt thereof having a structure represented by the following formula (2). The stabilizer may be used alone or in combination. By containing such a stabilizer in the reaction solution according to the type of radioactive metal nuclide, even when the radioactivity (charge radioactivity) at the start of the reaction is increased for the purpose of commercial production, it is possible to suppress the adsorption of radioactive metals or target radioactive metal complexes on the inner wall of the reaction vessel. As a result, the yield of the target radioactive metal complex can be increased.

[0071] [Chemical formula 3]

[0072]

[0073] In formula (2), R 21 -COOH, -CH2COOH, -CH2OH, -COOR 28 , -CONH2 or -CONHR 28 .

[0074] In formula (2), R 22 ~R 26 One or more and three or less groups in the group are hydroxyl groups (—OH), and the other groups are hydrogen atoms.

[0075] In formula (2), R 21 R 28 In the case of R 28 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted alkylaryl group. 28 Examples of the substituents include halogen atoms, saturated or unsaturated alkyl groups, hydroxyl groups, formyl groups, carboxyl groups, acyl groups, amino groups, nitro groups, ester groups, isothiocyanate groups, thioxy groups, cyano groups, amide groups, imide groups, phosphoric acid groups, phenyl groups, benzyl groups, pyridyl groups, etc. These substituents may be substituted alone or in combination of two or more thereof.

[0076] R 28 It may be straight chain or branched, and may be saturated or unsaturated.

[0077] R 28 The total number of carbon atoms is preferably 1 to 10, more preferably 1 to 8.

[0078] When the stabilizer represented by formula (2) is used in the form of a salt, examples of the counter ion include alkali metal ions such as sodium and potassium, and primary to quaternary ammonium cations such as ammonium and tetramethylammonium salts.

[0079] Examples of the structure of the stabilizer represented by formula (2) include structures represented by any of the following formulae (2a) to (2g), but the structure is not limited thereto.

[0080] [Chemical formula 4]

[0081]

[0082] In formula (2g), R 28 is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted alkylaryl. 28 Examples of the substituted substituent include halogen atoms, saturated or unsaturated alkyl groups, hydroxyl groups, formyl groups, carboxyl groups, acyl groups, amino groups, nitro groups, ester groups, isothiocyanate groups, sulfoxyl groups, cyano groups, amide groups, imide groups, phosphoric acid groups, phenyl groups, benzyl groups, pyridyl groups, etc. These substituents may be substituted alone or in combination of two or more thereof.

[0083] One embodiment of the stabilizer represented by formula (2) includes R 21 This embodiment is a carboxyl group (-COOH). That is, the stabilizer in this embodiment is hydroxybenzoic acid.

[0084] Examples of the hydroxybenzoic acid represented by formula (2) include monohydroxybenzoic acid, dihydroxybenzoic acid, and trihydroxybenzoic acid.

[0085] As monohydroxybenzoic acid, the following aspects are mentioned, for example.

[0086] 2-Hydroxybenzoic acid (salicylic acid): In formula (2), R 21 is -COOH, R 22 is -OH, R 23 ~R 26 All of them are hydrogen atoms. This embodiment corresponds to formula (2a).

[0087] ·3-Hydroxybenzoic acid: In formula (2), R 21 is -COOH, R 23 is -OH, R 22 , R 24 ~R 26 All are hydrogen atoms.

[0088] 4-Hydroxybenzoic acid: In formula (2), R 21 is -COOH, R 24 is -OH, R 22 , R 23 , R 25 and R 26 All are hydrogen atoms.

[0089] As dihydroxybenzoic acid, the following aspects can be mentioned.

[0090] ·2,3-Dihydroxybenzoic acid (2-pyrocatechuic acid): In formula (2), R 21 is -COOH, R 22 and R 23 All are -OH, R 24 ~R 26 All are hydrogen atoms.

[0091] ·2,4-dihydroxybenzoic acid (β-resorcinol): In formula (2), R 21 is -COOH, R 22 and R 24 All are -OH, R 23 , R 25 and R 26 All are hydrogen atoms.

[0092] 2,5-Dihydroxybenzoic acid (gentisic acid): In formula (2), R 21 is -COOH, R 22 and R 25 All are -OH, R 23 , R 24 and R 26 All of them are hydrogen atoms. This embodiment corresponds to formula (2b).

[0093] ·2,6-dihydroxybenzoic acid (γ-resorcinol): In formula (2), R 21 is -COOH, R 22 and R 26 All are -OH, R 23 , R 24 and R 25 All are hydrogen atoms.

[0094] ·3,4-dihydroxybenzoic acid (protocatechuic acid): In formula (2), R 21 is -COOH, R 23 and R 24 All are -OH, R 22 , R 25 and R 26 All of them are hydrogen atoms. This embodiment corresponds to formula (2c).

[0095] ·3,5-dihydroxybenzoic acid (α-resorcinol): In formula (2), R 21 is -COOH, R 23 and R 25 All are -OH, R 22 , R 24 and R 26 All are hydrogen atoms.

[0096] Examples of trihydroxybenzoic acid include the following, but are not limited to these.

[0097] ·3,4,5-Trihydroxybenzoic acid (gallic acid): In formula (2), R 21 is -COOH, R 23 ~R 25 All are -OH, R 22 and R 26 All of them are hydrogen atoms. This embodiment corresponds to formula (2d).

[0098] ·2,4,6-Trihydroxybenzoic acid: In formula (2), R 21 is -COOH, R 22 , R 24 and R 26 All are -OH, R 23 and R 25 All are hydrogen atoms.

[0099] Another embodiment of the stabilizer represented by formula (2) includes R 21 -CH2OH, -COOR 28 , or -CONHR 28 As the compound belonging to this embodiment, for example, the following embodiments can be mentioned, but it is not limited to this embodiment.

[0100] · Gentosan: In formula (2), R 21 is -CH2OH, R 22 and R 25 All are -OH, R 23 , R 24 and R 26 All of them are hydrogen atoms. This embodiment corresponds to formula (2e).

[0101] Gentisic acid alkyl ester: In formula (2), R 21 -COOR 28 , R 22 and R 25 All are -OH, R 23 , R 24 and R 26 are all hydrogen atoms, R 28 It is a saturated straight-chain alkyl group having 1 to 8 carbon atoms. This embodiment is one embodiment included in formula (2f).

[0102] Gentisic acid ethanolamide: In formula (2), R 21 For-CONHR 28 , R 22 and R 25 All are -OH, R 23 , R 24 and R 26are all hydrogen atoms, R 28 This embodiment is one embodiment included in formula (2g).

[0103] Among them, from the viewpoint of further improving the yield of the radioactive metal complex, as the stabilizer, it is preferred to use a compound having a structure represented by formula (2a) to (2g) or a salt thereof, more preferably to use a compound having a structure represented by any one of formula (2a) to (2d) or a salt thereof, and even more preferably to use a compound having a structure represented by formula (2b) or a salt thereof. That is, the stabilizer is more preferably salicylic acid, gentisic acid, protocatechuic acid or gallic acid or a salt thereof, more preferably salicylic acid, gentisic acid or protocatechuic acid or a salt thereof, and most preferably gentisic acid or a salt thereof.

[0104] From the viewpoint of further improving the yield of the radioactive metal complex, when a stabilizer is used, the concentration of the stabilizer in the reaction solution is preferably 0.1 mmol / L to 500 mmol / L at the beginning of the complex formation step, more preferably 1 mmol / L to 400 mmol / L, and even more preferably 1 mmol / L to 300 mmol / L. In addition, from the viewpoint of preventing radiodecomposition and thus further improving the labeling efficiency, the concentration of the stabilizer in the reaction solution is preferably higher than the concentration of the radioactive metal ion and the concentration of the ligand compound in the reaction solution.

[0105] In the present invention, the addition of a stabilizer is not necessary, but in the use 89 When Zr is used as a radioactive metal nuclide, it is preferable to add a stabilizer. 89 In the case of Zr, the above-mentioned adsorption easily causes a decrease in yield.

[0106] The reaction solution used in the complex formation process may not contain an organic solvent, or an organic solvent may be added according to the physical properties of the ligand compound and the stabilizer. As such an organic solvent, for example, water-soluble aprotic solvents such as protic solvents such as methanol and ethanol, acetonitrile, N,N-dimethylformamide, tetrahydrofuran, dimethyl sulfoxide and acetone, etc. may be cited. By including such an organic solvent, even when a water-insoluble substance is used as a ligand compound and a stabilizer, it can be fully dissolved or dispersed in a solvent, and a high labeling rate can be stably achieved.

[0107] The term “containing no organic solvent” means that the reaction liquid is not intentionally made to contain an organic solvent, but the inevitable mixing of the organic solvent into the reaction liquid is allowed.

[0108] The amount of the reaction solution in the complex forming step is not particularly limited, but from the viewpoint of the practicability of the production process, it is realistic to set the amount to 0.01 mL or more and 100 mL or less at the start of the complex forming step.

[0109] As far as the complex formation process is concerned, as long as the labeling reaction of the radioactive metal ion to the ligand compound can be carried out, in detail, as long as the radioactive metal ion and the ligand compound can form a complex, the order of adding the radioactive metal source, the ligand compound and other components is arbitrary. For example, one of the radioactive metal source and the ligand compound can be added to a reaction vessel in which a mixed solvent prepared by mixing water, a stabilizer and a second organic compound constituting the reaction solution is pre-accommodated, and then the other is added and reacted. Alternatively, the other can be added to a solution in which one of the radioactive metal source and the ligand compound is dissolved in a mixed solvent and reacted. Alternatively, the radioactive metal source and the ligand compound can also be added to a reaction vessel in which a mixed solvent is pre-accommodated at the same time to react.

[0110] In the complex formation step, in order to further improve the labeling efficiency with a short reaction time, the reaction solution is irradiated with microwaves. In this specification, microwaves refer to electromagnetic waves with a frequency of 10 MHz to 300 GHz. From the viewpoint of more effectively promoting the complex formation reaction, the frequency of the irradiated microwaves is preferably 800 MHz to 3 GHz, and more preferably 2.35 GHz to 2.55 GHz.

[0111] As the microwaves to be irradiated on the reaction solution, for example, microwaves oscillated by a magnetron type or semiconductor type microwave generator are preferably used.

[0112] The output of the microwaves to be irradiated is preferably 10 W or more, and more preferably 30 W or more. By setting the output of the microwaves to 10 W or more, the reaction rate of the complex formation step can be effectively increased.

[0113] In the complex forming step, microwaves may be irradiated at a fixed output power or may be varied over time within the above range. In addition, in the complex forming step, microwaves may be irradiated continuously or intermittently.

[0114] The microwave irradiation time can be set to the same time as the reaction time described below when the microwave is irradiated continuously. When the microwave is irradiated intermittently, the total microwave irradiation time can be preferably from 1 minute to 60 minutes, more preferably from 5 minutes to 30 minutes.

[0115] From the viewpoint of simultaneously suppressing the decomposition of the ligand compound and further improving the labeling efficiency, the temperature of the reaction solution is preferably 10°C to 90°C, more preferably 30°C to 80°C, and even more preferably 50°C to 70°C.

[0116] Under the above-mentioned reaction temperature conditions, the reaction time is preferably from 1 minute to 60 minutes, and more preferably from 5 minutes to 30 minutes.

[0117] In order to keep the output power of the microwave irradiated sufficiently high and prevent the temperature of the reaction solution from rising excessively, in the present invention, microwaves are irradiated to the reaction solution while the reaction solution is cooled. In this specification, the so-called "cooling of the reaction solution" includes an embodiment in which the reaction solution is directly cooled and an embodiment in which the reaction solution is indirectly cooled by exposing the reaction container containing the reaction solution to a cooling medium. From the viewpoint of the simplicity of operation, it is preferred to cool the reaction solution indirectly. In the embodiment in which the reaction solution is cooled indirectly, the heating of the reaction solution based on microwave irradiation and the cooling of the reaction solution based on a cooling medium are performed simultaneously to adjust the temperature of the reaction solution to remain within the above range.

[0118] The degree of cooling of the reaction solution may be constant throughout the complex forming step, or may be changed over time during the complex forming step.

[0119] Methods for changing the degree of cooling of the reaction solution over time include, for example, a method of changing the temperature of the cooling medium according to a predetermined schedule, a method of adjusting the temperature of the cooling medium according to the measured value of the temperature of the reaction solution to keep the temperature of the reaction solution within a target temperature range, or a method of temporarily stopping cooling.

[0120] Alternatively, the temperature of the reaction liquid may be maintained within the above range by varying the output power of the microwaves irradiated within the above range over time instead of varying the cooling degree over time while keeping the cooling degree constant. Alternatively, the temperature of the reaction liquid may be maintained within the above range by varying both the output power of the microwaves and the cooling degree over time.

[0121] The microwave irradiation and the cooling of the reaction solution may be performed continuously during the complex formation reaction, or one or both may be performed intermittently. From the viewpoint of improving the microwave irradiation effect, it is preferred to perform the microwave irradiation continuously during the complex formation reaction.

[0122] When starting the complex formation reaction, the irradiation of microwaves can be started before the cooling of the reaction solution, or the cooling of the reaction solution can be started before the irradiation of microwaves. Alternatively, both can be started simultaneously. From the viewpoint of preventing the temperature of the reaction solution from excessively rising, it is preferred to start the cooling of the reaction solution first. However, in the case where the temperature of the cooling medium is below the freezing point of the reaction solvent, in order to prevent the solidification of the reaction solution, it is preferred to start the irradiation of microwaves quickly after the cooling starts.

[0123] As the cooling medium used when indirectly cooling the reaction solution, gases such as air, liquids such as water and antifreeze, solids such as aluminum blocks can be cited. Among them, from the viewpoint of the ease of temperature control, precision and cooling efficiency, it is preferred to use air as the cooling medium, that is, to cool the reaction solution by exposing the reaction vessel to cold wind.

[0124] From the viewpoint of facilitating the temperature adjustment of the reaction solution, the temperature of the cooling medium is preferably -196°C to 90°C, more preferably -35°C to 25°C, and even more preferably -10°C to 0°C.

[0125] As described in the examples described below, in the present invention, by irradiating a reaction solution containing a stabilizer with microwaves, the effect of increasing the yield of the radioactive metal complex by microwave irradiation can be further enhanced compared to the case where a reaction solution not containing a stabilizer is irradiated with microwaves.

[0126] The complex formation step is preferably carried out under the condition that the pH of the reaction solution is in the acidic region. That is, in the complex formation step, it is preferred to carry out the reaction under the condition that the pH is maintained in the acidic state during the period from the start of the reaction to the end. The so-called pH of the reaction solution is in the acidic region, which means that the pH of the reaction solution is less than 7. By carrying out the reaction under the condition that the pH of the reaction solution is in the acidic region, the functional group of the ligand compound that interacts with the radioactive metal and / or the radioactive metal can be appropriately maintained in an ionic state, and a state that is easy to coordinate with each other can be maintained in the reaction solution. As a result, the productivity of the radioactive metal complex can be further improved.

[0127] More specifically, the complex forming step is performed in a state where the pH of the reaction solution is preferably 2.0 to 6.0.

[0128] The pH of the reaction solution can be maintained in the acidic region even in the complex forming step by adjusting the pH of the reaction solution to the acidic region before starting the reaction, that is, before carrying out the complex forming step.

[0129] For example, the pH of the reaction solution can be adjusted by mixing an aqueous solution of the second organic compound and / or a stabilizer in the reaction solution. Alternatively, the pH of the reaction solution can be adjusted by adjusting the mixing ratio of the liquid containing radioactive metal ions, the aqueous solution of the ligand compound, the aqueous solution of the second organic compound, and the aqueous solution of the stabilizer after the liquid containing radioactive metal ions, the ligand compound, the aqueous solution of the second organic compound, and the aqueous solution of the stabilizer are prepared in advance. Alternatively, an inorganic acid such as hydrochloric acid or a metal hydroxide such as sodium hydroxide can be added to the liquid mixed with the radioactive metal ions, the ligand compound, the second organic compound, and the stabilizer to adjust the pH of the reaction solution.

[0130] In the complex formation step, from the viewpoint of improving the production efficiency of the radioactive metal complex, the amount of radioactivity of the radioactive metal nuclide in the reaction solution at the start of the reaction is preferably set as follows.

[0131] In use 89 In the embodiment where Zr is the radioactive metal nuclide, the amount of radioactivity in the reaction solution at the start of the reaction in the complex formation step is: 89 The amount of radioactivity of Zr is set to 5 MBq or more, preferably 15 MBq or more, and more preferably 50 MBq or more.

[0132] In use 225 In the embodiment where Ac is a radioactive metal nuclide, the amount of radioactivity in the reaction solution at the start of the complex formation step is, 225 The amount of radioactivity of Ac is set to 1 MBq or more, preferably 2 MBq or more, and more preferably 4 MBq or more.

[0133] In any embodiment, the upper limit of the amount of radioactivity in the reaction solution at the start of the reaction is not particularly limited as long as it is an amount of radioactivity that can be achieved on a commercial production scale, and may be, for example, 1000 GBq or less.

[0134] In addition, in the complex formation reaction, from the viewpoint of reducing the amount of the ligand compound used and suppressing the production cost of the radioactive metal complex, it is preferred that the ratio of the amount of the radioactive metal nuclide in the reaction solution at the start of the reaction to the amount of the ligand compound be greater than the value described below.

[0135] In use 89In the embodiment in which Zr is used as the radioactive metal nuclide, as the ratio of the amount of the ligand compound and the amount of the radioactivity in the reaction solution at the start of the reaction, the amount of the radioactivity of the radioactive metal nuclide per 1 nmol of the ligand compound is preferably set to 10 MBq or more, more preferably set to 20 MBq or more, and further preferably set to 60 MBq or more. The upper limit is not particularly limited, for example, 10000 MBq or less.

[0136] In use 225 In the embodiment where Ac is a radioactive metal nuclide, as the ratio of the amount of the ligand compound and the amount of the radioactivity in the reaction solution at the start of the reaction, the amount of the radioactivity of the radioactive metal nuclide per 1 nmol of the ligand compound is preferably set to 0.3 MBq or more, more preferably to 1 MBq or more, and further preferably to 2 MBq or more. The upper limit is not particularly limited, for example, 10000 MBq or less.

[0137] Generally, if the amount of radioactivity of the radiometal nuclide per 1 nmol of the ligand compound is increased, the yield of the complex formation reaction tends to decrease. However, in the present invention, the complex formation reaction is effectively promoted by microwave irradiation, so even when the amount of radioactivity of the radiometal nuclide per 1 nmol of the ligand compound is increased to the above range, the complex formation reaction is carried out with a high yield.

[0138] The reaction pressure in the complex formation step can be set to atmospheric pressure.

[0139] In the manufacturing method of the present invention having the above-mentioned complex formation step, the complex formation reaction is carried out while irradiating microwaves of sufficiently high output power, so compared with the prior art of heating without irradiating microwaves and the prior art of microwave irradiation conditions not optimized, the speed of the complex formation reaction can be increased. Thus, even in a short reaction time, a radioactive metal complex can be manufactured in high yield. In addition, the manufacturing method of the present invention prevents the temperature of the reaction solution from excessively rising by irradiating microwaves to the reaction solution while cooling the reaction solution, thereby increasing the output power of the irradiated microwaves. Thus, the side reactions caused by the excessive temperature rise of the reaction solution can be suppressed.

[0140] The production method of the present invention is also advantageous in that the yield of the obtained radioactive metal complex is high, and therefore the complex can be used in a subsequent step without separating and purifying unreacted radioactive metal nuclides.

[0141] The improved operability of the ligand compound used and the 89From the viewpoint of improving the stability of the Zr complex, especially the stability of the complex formation, in formula (1), R 11 , R 12 and R 13 All are composed of -(CH2) p The group composed of COOH represents a carboxyalkyl group, and p is an integer of 1 to 3.

[0142] In this case, R is also preferably 14 and R 15 One of them is a hydrogen atom, or -(CH2) p The group consisting of COOH represents a carboxyalkyl group, and p is an integer of 1 to 3. In this case, R 14 and R 15 The other is -(CH2) p The group composed of COOH represents a carboxyalkyl group, wherein p is an integer of 1 to 3, or is a reactive atomic group for connecting to a targeting agent or a group already connected to a targeting agent.

[0143] R 11 , R 12 , R 13、 R 14 and R 15 When having the above-mentioned preferred groups, R 14 and R 15 When one of them is a hydrogen atom, R 14 and R 15 The other one is preferably a reactive atomic group for linking with a targeting agent or a group already linked with a targeting agent.

[0144] That is, it is preferred that R 14 In the case where R is a reactive atomic group for connecting to a targeting agent or a group already connected to a targeting agent, 15 For hydrogen atoms, in R 15 In the case where R is a reactive atomic group for connecting to a targeting agent or a group already connected to a targeting agent, 14 A hydrogen atom.

[0145] In the case of using a ligand compound containing a group connected to a targeting agent in formula (1), as the targeting agent, it is preferably one or more of the following atomic groups, wherein the atomic group includes a substance selected from a low molecular weight compound, a polypeptide, a peptide aptamer, a growth factor, an affibody, a unibody, a nanobody, a monosaccharide, a polysaccharide, a vitamin, a nucleic acid, a liposome, a micelle, a carbon nanotube, or a nanoparticle. Among them, from the viewpoint of medical use, the targeting agent is more preferably a low molecular weight compound, a polypeptide or a nucleic acid.

[0146] It should be noted that the so-called low molecular weight compound refers to, for example, a compound having a structure with targeting properties or a compound having an atomic group capable of undergoing a click reaction.

[0147] The term "targeting agent" as used herein refers to a chemical structure that is used to express directivity to a target organ or tissue in a living body, or specificity to a target molecule. In this specification, target organs or tissues or target molecules are also collectively referred to as "target sites".

[0148] These targeting agents may be directly bonded to the ligand compound, or may be indirectly bonded via other known linker structures such as PEG.

[0149] In addition, these targeting agents can also be formed by modifying reactive atomic groups capable of bonding to other structures so as to be linked to ligand compounds. For example, known reactions such as click reactions can be used to link to ligand compounds.

[0150] When click reaction is used for linkage, for example, both the reactive atomic group of the targeting agent and the reactive atomic group of the ligand compound for linkage with the targeting agent may be groups containing an atomic group capable of click reaction.

[0151] By using a ligand compound having such a chemical structure, it can be easily bonded to a targeting agent that is specific or directed toward the target site, and a radioactive metal complex that is specific or directed toward the target site can be obtained in high yield while fully maintaining the specificity or directedness of the targeting agent toward the target site.

[0152] When the targeting agent comprises a polypeptide, the targeting agent is preferably a chain peptide, a cyclic peptide or a combination thereof or a protein that can be bonded to a specific molecule specifically. As an example of such an atomic group, a peptide having an amino acid residue of more than 3 residues can be cited. From the viewpoint of being able to be chemically controlled and synthesized, the molecular weight of the aforementioned peptide is preferably more than 500 and less than 20,000, more preferably more than 1,000 and less than 6,000.

[0153] Furthermore, the polypeptide may be an antibody or a fragment thereof. Examples thereof include antibodies (immunoglobulins) of the types IgG, IgA, IgM, IgD and IgE, antibody fragments such as Fab fragments and F(ab')2 fragments, and peptide aptamers.

[0154] The amino acids constituting the above-mentioned targeting agent may be natural amino acids or synthetic amino acids.

[0155] Various polypeptides that can be used in targeting agents can be synthesized using methods known in the past, such as liquid phase synthesis, solid phase synthesis, automatic peptide synthesis, gene recombination, phage display, genetic codon reprogramming, RaPID (Random non-standard Peptide Integrated Discovery) and other methods. When synthesizing various polypeptides, the functional groups of the amino acids used can also be protected as needed.

[0156] When the targeting agent is an atomic group containing nucleic acid, the atomic group is preferably an atomic group containing antisense nucleic acid, siRNA, miRNA, nucleic acid aptamer, decoy nucleic acid, cPG oligonucleic acid, peptide nucleic acid that can be specifically bonded to a specific molecule. In addition, the nucleic acid base constituting such a targeting agent can be a natural nucleic acid base such as deoxyribonucleic acid and ribonucleic acid, or a synthetic nucleic acid base.

[0157] The atomic group containing the above-mentioned nucleic acid that can be used in the present invention can be manufactured using a previously known method. For example, in the case of nucleic acid aptamers, the SELEX method (Systematic Evolution of Ligands by Exponential Enrichment) can be used to manufacture nucleic acid aptamers that can specifically bond to specific target substances such as proteins.

[0158] When the ligand compound containing a reactive atomic group for linking to a targeting agent used in the present invention contains an atomic group capable of click reaction, the atomic group capable of click reaction can be appropriately used from known reagents that can be used for click reaction.

[0159] In this specification, the "reactive atomic group" refers to a chemical structure that directly causes a reaction when one compound is bonded to another compound. Examples of such reactive atomic groups include atomic groups that can undergo click reactions, but are not limited thereto.

[0160] Examples of the atomic group capable of undergoing a click reaction include an alkynyl group or an azide group, or a diene or a dienophile such as 1,2,4,5-tetrazine or an alkenyl group.

[0161] From the viewpoint of the convenience of realizing the click reaction step, the atomic group capable of performing a click reaction as the reactive atomic group is preferably an atomic group that can be used for a click reaction without a metal catalyst.

[0162] Click reactions are reactions that occur, for example, using a combination of alkynes and azides, or a combination of 1,2,4,5-tetrazine and a diene such as an olefin and a dienophile. Specific examples of click reactions that occur using such a combination of atomic groups include Huisgen cycloaddition reactions and Diels-Alder reactions.

[0163] Typically, the chemical structure generated by the click reaction using a combination of alkynes and azides includes a triazole skeleton, and the chemical structure generated by the click reaction using a combination of 1,2,4,5-tetrazines and alkenes as a combination of dienes and dienophiles includes a pyridazine skeleton. Therefore, as an atomic group that can be included in the reaction atomic group for connection with a targeting agent and can be subjected to a click reaction, when it is an atomic group containing alkynes or azides, a triazole skeleton can be formed by a click reaction. In addition, as an atomic group that can be included in the reaction atomic group for connection with a targeting agent and can be subjected to a click reaction, when it contains an atomic group containing 1,2,4,5-tetrazines or alkenes as a diene or dienophile, a pyridazine skeleton can be formed by a click reaction.

[0164] Specific examples of atomic groups capable of undergoing click reactions include, as shown in the following formulas, an atomic group comprising dibenzylcyclooctyne (DBCO) as an alkyne (Formula (5a)), an atomic group comprising an azide group as an azide (Formula (5b)), an atomic group comprising 1,2,4,5-tetrazine (Formula (5c)), or an atomic group comprising trans-cyclooctene (TCO) as an olefin (Formula (5d)).

[0165] [Chemical formula 5]

[0166] (5a) (5b)

[0167] [Chemical formula 6]

[0168] (5c) (5d)

[0169] In formula (5a), R1 represents a bonding site to an atomic group including a ligand compound or a targeting agent.

[0170] In formula (5b), R2 represents a bonding site to an atomic group including a ligand compound or a targeting agent.

[0171] In formula (5c), one of R3 and R4 represents a bonding site to an atomic group including a ligand compound or a targeting agent, and the other represents a hydrogen atom, a methyl group, a phenyl group or a pyridyl group.

[0172] In formula (5d), R5 represents a bonding site to an atomic group including a ligand compound or a targeting agent.

[0173] When introducing an atomic group capable of click reaction into the ligand compound, various commercially available reagents can be used for introduction. Specifically, when introducing an atomic group containing dibenzylcyclooctyne (DBCO) as an atomic group capable of click reaction, DBCO reagents such as DBCO-C6-Acid, DBCO-Amine, DBCOMaleimide, DBCO-PEG acid, DBCO-PEG-NHS ester, DBCO-PEG-Alcohol, DBCO-PEG-amine, DBCO-PEG-NH-Boc, Carboxyrhodamine-PEG-DBCO, Sulforhodamine-PEG-DBCO, TAMRA-PEG-DBCO, DBCO-PEG-Biotin, DBCO-PEG-DBCO, DBCO-PEG-Maleimide, TCO-PEG-DBCO, and DBCO-mPEG can be used.

[0174] As the preferred ligand compound used in the present invention, for example, a compound having a structure shown in the following formula (1-a) to (1-e) can be used, but it is not limited to these. When it is a ligand compound with any structure, the effect of stable improvement of the labeling rate can be fully exerted. In the following formulas, P represents an atomic group containing a reactive atomic group or an atomic group containing a targeting agent. From the viewpoint of achieving a stable improvement in the labeling rate, it is more preferred to use a ligand compound having a structure represented by the above-mentioned formula (1-c).

[0175] [Chemical formula 7]

[0176]

[0177] [Chemical formula 8]

[0178] (1-e)

[0179]

[0180] When a ligand compound containing an atomic group capable of click reaction in formula (1) is used, it is also preferred that the ligand compound and the atomic group capable of click reaction are indirectly bonded via a linker structure represented by the following formula (P). This structure is a structure derived from ethylene glycol, and in formula (P), n is preferably an integer of 2 to 10, and more preferably an integer of 2 to 8.

[0181] [Chemical formula 9]

[0182] (P)

[0183] The structure of the ligand compound containing an atomic group capable of click reaction is not particularly limited as long as it can exert the effect of the present invention, and it is further preferred to have the structure shown below. That is, the ligand compound further preferably has at least one of DO3A-DBCO, DOTA-DBCO, DO3A-PEG4-DBCO, DO4A-PEG7-Tz, and DOTAGA-DBCO shown below.

[0184] [Chemical formula 10]

[0185]

[0186] [Chemical formula 11]

[0187]

[0188] When using a ligand compound containing an atomic group capable of undergoing a click reaction as a reactive atomic group, for example, the ligand compound can be coordinated to a radioactive metal nuclide using the above-mentioned method, and then the atomic group capable of undergoing a click reaction possessed by the ligand compound is reacted with the atomic group capable of undergoing a click reaction in the targeting agent through a click reaction, etc., thereby producing a radioactive metal complex.

[0189] In this case, the targeting agent may be a compound modified with an atomic group capable of specifically bonding to a reactive atomic group in the ligand compound and capable of performing a click reaction.

[0190] As the atomic group capable of click reaction for modifying the targeting agent, the same atomic group as the atomic group capable of click reaction described above can be used. By using such a compound, a radioactive metal complex having specificity or directivity to a target site can be produced.

[0191] The radioactive metal complex generated by the above steps exists in a state of being dissolved in the reaction solution. That is, the radioactive metal complex can be obtained in the form of an aqueous liquid. For the aqueous liquid containing the radioactive metal complex, it can be used directly, or it can also be purified using a filter, a membrane filter, a column filled with various fillers, chromatography, etc.

[0192] As a step after obtaining the radioactive metal complex, for example, a preparation step for obtaining a radiopharmaceutical with the radioactive metal complex as an active ingredient can be cited. The preparation step can be performed by appropriately adding pH adjusters such as citrate buffer, phosphate buffer, borate buffer, solubilizers such as polysorbate, stabilizers or antioxidants, or by adjusting the radioactivity concentration by diluting with water, physiological saline solution, or isotonic solution. In addition, as a preparation step, after adding various stabilizers or adjusting the concentration, a step of preparing an injection by sterilizing filtration using a membrane filter or the like can be included.

[0193] The above-mentioned embodiments of the present invention include the following technical concepts.

[0194] [1] A method for producing a radioactive metal complex, comprising: reacting a radioactive metal nuclide with a ligand compound represented by the above formula (1) in a reaction solution containing water and a buffer to form a radioactive metal complex;

[0195] The buffer comprises one or more water-soluble organic compounds having a sulfonic group or a carboxyl group,

[0196] In the complex forming step, the reaction solution is irradiated with microwaves while the reaction solution is cooled.

[0197] [2] The production method according to [1], wherein the radioactive metal nuclide is 68 Ga, 89 Zr, 90 Y. 111 In, 177 Lu or 225 Ac.

[0198] [3] The production method according to [1] or [2], wherein the radioactive metal nuclide is 89 Zr.

[0199] [4] The production method according to any one of [1] to [3], wherein the reaction solution contains a stabilizer.

[0200] [5] The production method according to [4], wherein the stabilizer is one or more selected from gentisic acid, salicylic acid, protocatechuic acid and salts thereof.

[0201] [6] The production method according to any one of [3] to [5], wherein at the beginning of the complex formation step, 10 MBq or more of the radioactive metal nuclide is used per 1 nmol of the ligand compound.

[0202] [7] The production method according to [2], wherein the radioactive metal nuclide is225 Ac.

[0203] [8] The production method according to [7], wherein at the beginning of the complex formation step, 0.3 MBq or more of the radioactive metal nuclide is used per 1 nmol of the ligand compound.

[0204] [9] The production method according to any one of [1] to [8], wherein the targeting agent is a low molecular weight compound, a polypeptide or a nucleic acid.

[0205]

[10] The production method according to any one of [1] to [9], wherein the reaction solution contains an organic solvent.

[0206]

[11] The production method according to

[10] , wherein the organic solvent is one or more selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and ethanol.

[0207]

[12] The production method according to any one of [1] to

[11] , wherein the pH of the reaction solution is in an acidic region.

[0208]

[13] A production method as described in any one of [1] to

[12] , wherein the water-soluble organic compound is one or more selected from acetic acid, phthalic acid, malonic acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, 3-morpholinepropanesulfonic acid and their salts.

[0209]

[14] The production method according to any one of [1] to

[13] , wherein the temperature of the reaction solution is 10° C. to 90° C.

[0210]

[15] The production method according to any one of [1] to

[14] , wherein in the complex formation step, the reaction solution is irradiated with microwaves at an output of 10 W or more.

[0211]

[16] The production method according to any one of [1] to

[15] , wherein in the complex formation step, irradiation is performed using microwaves oscillated by a magnetron type or semiconductor type microwave generator.

[0212]

[17] The production method according to any one of [1] to

[16] , wherein in the complex formation step, the container containing the reaction solution is cooled by exposing it to cold air.

[0213] Example

[0214] The present invention is described in more detail below using examples. However, the scope of the present invention is not limited to the examples. The following examples and comparative examples are all carried out under atmospheric pressure, and the reaction temperature of the complex formation reaction is set to 70° C. In addition, the pH of the reaction solution at the start of the reaction is 4.0 to 5.5 in any of the examples and comparative examples.

[0215] In the following examples and comparative examples, the radioactive Zr element, the ligand compound and the stabilizer were respectively used: 89 Zr, DOTAGA-DBCO and gentisic acid. In addition, acetic acid and sodium acetate were used as the second organic compound.

[0216] from 89 Zr ions are removed from the bulk solution 89 Zr and use. 89 The bulk solution of Zr ions used the following batches A to D. Batch A: Production of 3.9 GBq 89 Zr after 4 days of bulk solution. Batch B: 11.8 GBq 89 Zr bulk solution after 1 day. Batch C: 8.8 GBq 89 Batch D: 8.8 GBq of Zr was produced 89 The bulk solution after 6 days after Zr.

[0217] Since the reaction results of the complex formation reaction (labeling rate, adsorption rate, theoretical yield, etc. described below) are affected by the batch of the bulk solution, the comparison of the reaction results of each example and comparative example needs to be performed between the examples and comparative examples using the same batch.

[0218] [Example 1]

[0219] (Preparation of reaction solution)

[0220] Dispense 0.1 mL of 89 The radioactivity of the bulk solution of Zr ions (batch A, solvent: 1.0 mol / L hydrochloric acid) was measured using a radioisotope dose calibrator (manufactured by CAPINTEC). The measured radioactivity was 1491 MBq.

[0221] Next, the vial was heated at 110°C for 40 minutes under an argon stream to distill off the solvent. 100 μL of 0.1 mol / L hydrochloric acid was added to the resulting residue to prepare a solution containing the radioactivity concentration to be measured. 89 Zr ion solution (radioactivity concentration: 14910 MBq / mL).

[0222] Include this 89A portion of the Zr ion solution (the amount required to make the charge radioactivity 7.20 MBq) was added to a 10 mL glass tube, and 0.1 mol / L hydrochloric acid was further added to prepare a 200 μL solution (hereinafter also referred to as "solution 1").

[0223] Next, 200 μL of 0.156 mol / L acetic acid-sodium acetate buffer (hereinafter, also referred to as "solution 2") containing gentisic acid at a concentration of 150 mmol / L and 200 μL of 0.156 mol / L acetic acid-sodium acetate buffer (hereinafter, also referred to as "solution 3") containing DOTAGA-DBCO at a concentration of 0.01 mmol / L were added in sequence, and the glass tube was stirred. The reaction solution contained 1 nmol of the ligand compound (DOTAGA-DBCO) 89 The radioactivity of Zr (hereinafter also referred to as "specific radioactivity") was 3.6 MBq / nmol, and the volume of the reaction solution was 600 μL.

[0224] (Complex Formation Step)

[0225] Next, a semiconductor microwave generator (manufactured by Linghe Electronics Co., Ltd., MR-2G-100-CA50T15AC) was used to carry out the complex formation reaction. First, cold air was blown into the glass tube to start cooling the reaction liquid in the glass tube, and then microwave irradiation of the reaction liquid was immediately started. As for the output power of the microwave, the maximum output power was set to 100 W. During the complex formation reaction, the microwave output power was varied in such a way that the temperature of the reaction liquid was kept constant at 70°C, and irradiation was performed continuously. The temperature of the cold air was set to -5°C to -10°C. During the complex formation reaction, cold air within the aforementioned temperature range was continuously blown into the glass tube. After 10 minutes from the start of microwave irradiation, the supply of cold air and microwave irradiation were stopped.

[0226] (Analysis of Reaction Products)

[0227] 2 μL was extracted from the reaction solution for thin layer chromatography (TLC) analysis. TLC conditions: iTLC-SG (Agilent), developing solvent: water / acetonitrile mixture (volume ratio 1:1)

[0228] The developed thin layer chromatogram was introduced into a TLC analyzer (GITAStar, manufactured by Raytest) to measure the content of the reaction solution including the unreacted 89 Total Zr 89 Zr radioactivity counting and 89 The radioactivity of the Zr complex is counted. Then, 89 The radioactivity counts of the Zr complexes were relative to the total 89The percentage of Zr radioactivity counts is taken as labeling rate (%). The labeling rate indicates the degree of progress of the labeling reaction. The higher the labeling rate, the more target is generated. 89 The presence of a Zr complex means that the labeling reaction proceeds well. The labeling rate of this sample is 91%.

[0229] in addition, 89 The adsorption rate (%) of the Zr complex was calculated based on the adsorption amount confirmed by measuring the amount of radioactivity in the reaction container after the reaction solution was taken out using a radioisotope dose calibrator (manufactured by CAPINTEC). The adsorption rate represents the amount of Zr adsorbed on the inner wall of the reaction container. 89 The ratio of the radioactivity of Zr to the radioactivity of the charge. The adsorption rate of this sample is 19%.

[0230] Next, we calculate 89 Theoretical yield of Zr complex (%). Theoretical yield (%) = labeling rate (%) × (100-adsorption rate (%)) / 100

[0231] The theoretical yield calculated by the above formula represents the amount of water that can be taken out from the reaction vessel and used. 89 Zr complex relative to 89 The theoretical yield of this sample is 74%.

[0232] [Examples 2 to 6, Comparative Examples 1 to 7]

[0233] In addition to making 89 The same procedures as in Example 1 were carried out except that the batch of the bulk solution of Zr ions, the charge radioactivity, the addition amount of solutions 1 to 3, the concentration of the ligand compound DOTAGA-DBCO contained in solution 3, the reaction time and the heating method were as described in Table 1, to produce Examples 2 to 6 and Comparative Examples 1 to 7. 89 The labeling rate, adsorption rate and theoretical yield of Zr complex are shown in Table 1.

[0234] It should be noted that in Comparative Examples 1 to 7, the reaction solution was heated using a block heater instead of irradiating microwaves. This also applies to Comparative Examples 8 to 10 described later. In Table 1 and Tables 2 and 4 described later, the semiconductor microwave generator is described as "semiconductor MW".

[0235] [Table 1]

[0236]

[0237] As shown in Table 1, when comparing Examples 1 to 4, the lower the radioactivity ratio, the higher the target 89In Examples 5 and 6, a batch containing a small amount of non-radioactive metal nuclides as impurities was used. 89 In this case, although the radioactivity ratio is as high as 81 to 100 MBq / nmol, it can still be obtained with a high theoretical yield. 89 For Comparative Examples 1 to 7 in which the reaction solution was heated by a block heater without microwave irradiation, the radioactivity ratio and 89 Compared with the same batch of bulk solution of Zr ions, the theoretical yield is low. According to this comparison, microwave irradiation has the effect of effectively promoting the complex formation reaction. In addition, it is known that by irradiating microwaves, even when the radioactivity ratio is increased, a radioactive metal complex can be obtained with a high yield.

[0238] In addition, when comparing Example 1 in which microwaves were irradiated and reacted for 10 minutes with Comparative Example 2 in which a block heater was used and reacted for 60 minutes, the labeling rate and theoretical yield were comparable, indicating that microwave irradiation can shorten the reaction time to about 1 / 6.

[0239] [Examples 7 to 10, Comparative Example 8]

[0240] In addition to making 89 The same procedures as in Example 1 were carried out except that the batch of the bulk solution of Zr ions, the charge radioactivity, the addition amount of solutions 1 to 3, the concentration of the ligand compound DOTAGA-DBCO contained in solution 3, and the heating method were as described in Table 2, to produce Examples 7 to 10 and Comparative Example 8. 89 The labeling rate, adsorption rate and theoretical yield of Zr complex are shown in Table 2.

[0241] In addition, in Table 2 and Table 3 described later, the magnetron microwave generator is expressed as "magnetron MW." In addition, the magnetron microwave generator used was Discover manufactured by CEM.

[0242] [Table 2]

[0243]

[0244] As shown in Table 2, when using any of the semiconductor microwave generator (Examples 7 and 8) and the magnetron microwave generator (Examples 9 and 10), the target compound was obtained with a significantly higher theoretical yield than in Comparative Example 8 in which a complex formation reaction was performed using a block heater without irradiating microwaves. 89 In addition, no significant difference was observed between the semiconductor type microwave generator and the magnetron type microwave generator, and it was found that the reaction acceleration effect was similar regardless of which one was used.

[0245] [Examples 11 to 14, Comparative Examples 9 to 10]

[0246] In addition to making 89 Except that the batch of the bulk solution of Zr ions, the charge radioactivity, the addition amount of solutions 1 to 3, the reaction time, the heating method and the maximum output power of the microwave were as described in Table 3, the same operation as in Example 1 was carried out to produce Examples 11 to 14 and Comparative Examples 9 to 10. 89 The labeling rate, adsorption rate and theoretical yield of these Zr complexes are shown in Table 3.

[0247] [Table 3]

[0248]

[0249] In Examples 11 to 14, in which the maximum microwave output was set at 20 to 100 W, the target product was obtained at a higher theoretical yield than in Comparative Example 9, in which the product was heated by a block heater without microwave irradiation. 89 Zr complex. Especially when the maximum output power of the microwave is set to 60W, 89 The theoretical yield of the Zr complex is the highest. In addition, for Examples 11 to 13 in which the maximum microwave output power is set to 40 to 100 W and the reaction is performed for 10 minutes, a high theoretical yield is obtained compared to Comparative Example 10 in which the reaction is performed for 60 minutes without microwave irradiation. Therefore, it can be seen that under these reaction conditions, the reaction time can be shortened to less than 1 / 6 compared to the case of not irradiating microwaves.

[0250] [Examples 15-16]

[0251] make 89 The batch of Zr ion bulk solution, charge radioactivity, addition amount of solution 1 to 3, heating method and maximum microwave output power are as shown in Table 4, and microwave irradiation is switched on / off every 10 seconds. The same operation as in Example 1 was performed to produce Example 15. 89 In Example 16, the same operation as in Example 15 was performed except that Solution 2 containing no gentisic acid as a stabilizer was used to produce Example 16. 89 The labeling rate, adsorption rate and theoretical yield of these Zr complexes are shown in Table 4.

[0252] [Table 4]

[0253]

[0254] As shown in Table 4, it can be seen that Example 16 without using gentisic acid has a higher adsorption rate and a lower theoretical yield than Example 15 using gentisic acid. That is, in the present invention, the effect of promoting the complex formation reaction by microwave irradiation and the effect of suppressing the adsorption of the radioactive metal complex by the stabilizer are combined, so that the radioactive metal complex can be produced more efficiently.

Claims

1. A method for producing a radioactive metal complex, comprising: reacting a radioactive metal nuclide with a ligand compound represented by the following formula (1) in a reaction solution containing water and a buffer to form a radioactive metal complex; The buffer comprises one or more water-soluble organic compounds having a sulfonic group or a carboxyl group, In the complex formation step, the reaction solution is irradiated with microwaves while the reaction solution is cooled. [Chemical formula 1] In formula (1), R 11 , R 12 and R 13 Each independently consists of -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, or -(CH2) p The group composed of CONH2, R 14 or R 15 One of them is composed of hydrogen atoms, -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, -(CH2) p CONH2, or -(CHCOOH)(CH2) p COOH, and the other is -(CH2) p COOH, -(CH2) p C5H4N, -(CH2) p PO3H2, or -(CH2) p The group composed of CONH2 is either a reactive atomic group for connecting to a targeting agent or a group already connected to a targeting agent, and p is each independently an integer of 0 to 3.

2. The manufacturing method according to claim 1, wherein: The radioactive metal nuclide is 68 Ga, 89 Zr, 90 Y. 111 In, 177 Lu or 225 Ac.

3. The manufacturing method according to claim 2, wherein: The radioactive metal nuclide is 89 Zr.

4. The manufacturing method according to claim 3, wherein: The reaction solution contains a stabilizer.

5. The manufacturing method according to claim 4, wherein: The stabilizer is one or more selected from gentisic acid, salicylic acid, protocatechuic acid and salts thereof.

6. The manufacturing method according to claim 3 or 4, wherein: At the beginning of the complex formation step, 10 MBq or more of the radioactive metal nuclide is used per 1 nmol of the ligand compound.

7. The manufacturing method according to claim 2, wherein: The radioactive metal nuclide is 225 Ac.

8. The manufacturing method according to claim 7, wherein: At the beginning of the complex formation step, 0.3 MBq or more of the radioactive metal nuclide is used per 1 nmol of the ligand compound.

9. The manufacturing method according to claim 1 or 2, wherein: The targeting agent is a low molecular compound, a polypeptide or a nucleic acid.

10. The manufacturing method according to claim 1 or 2, wherein: The reaction solution contains an organic solvent.

11. The manufacturing method according to claim 10, wherein: The organic solvent is one or more selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and ethanol.

12. The manufacturing method according to claim 1 or 2, wherein: The pH of the reaction solution is in the acidic region.

13. The manufacturing method according to claim 1 or 2, wherein: The water-soluble organic compound is one or more selected from acetic acid, phthalic acid, malonic acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, 3-morpholinepropanesulfonic acid and their salts.

14. The manufacturing method according to claim 1 or 2, wherein: The temperature of the reaction solution is 10° C. or higher and 90° C. or lower.

15. The manufacturing method according to claim 1 or 2, wherein: In the complex formation step, the reaction solution is irradiated with microwaves at an output of 10 W or more.

16. The manufacturing method according to claim 1 or 2, wherein: In the complex formation step, microwaves oscillated using a magnetron type or semiconductor type microwave generator are irradiated.

17. The manufacturing method according to claim 1 or 2, wherein: In the complex forming step, the container containing the reaction solution is cooled by exposing it to cold air.

Citation Information

Patent Citations

  • SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225

    US20150157742A1